Navigation Links
Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results

FORT MYERS, Fla., May 11, 2011 /PRNewswire/ -- Radiation Therapy Services Holdings, Inc. (the “Company”), a leading operator of radiation therapy centers, today announced financial results for the first quarter ended March 31, 2011.

Total revenues for the first quarter of 2011 were $156.5 million, an increase of 16.4% compared to $134.5 million in revenue in the same quarter of 2010. The increase in revenue was principally due to revenue from the May 2010 acquisition of the Myrtle Beach, South Carolina physician practices and the March 2011 acquisition of Medical Developers, LLC (“Medical Developers”), which operates 26 radiation oncology centers in Latin America, of $9.9 million and $5.2 million, respectively.  In addition, the Company issued $66.3 million of its 9.875% senior subordinated notes due 2017 to facilitate the acquisition of Medical Developers.  

For the first quarter 2011, the Company reported an average of 2,004 total treatments per day at its domestic freestanding radiation oncology centers, up 3.7% as compared to the same period in 2010.

Same practice therapy revenue increased 3.3% from the first quarter of 2010 principally as a result of a mix shift towards more clinically sophisticated radiation oncology services, which resulted in an increase in Relative Value Units (“RVUs”) and an additional treatment day, both partially offset by a reduction in the conversion factor for fiscal year 2011.

Total RVUs per day at domestic freestanding centers increased 16.5% in the first quarter of 2011 versus the same period of the prior year principally as a result of an increase in RVU values in 2011 and a mix shift towards more clinically sophisticated radiation oncology services.

Adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation and other non-cash and pro forma items (“Pro Forma Adjusted EBITDA”) increased 21.1% in the first quarter of 2011 to $31.2 million, or 18.9% of total pro forma revenues, from $25.7 million, or 19.1% of total pro forma revenues, in the first quarter of 2010.  A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc. shareholder determined in accordance with generally accepted accounting principles to Pro Forma Adjusted EBITDA and total revenues determined in accordance with generally accepted accounting principles to total pro forma revenues for the quarters ended March 31, 2011 and 2010 is included in the attached supplemental information.  

The net loss for the first quarter of 2011 was $3.1 million, compared to a net loss of $1.0 million in the first quarter of 2010.  The increase in net loss for the first quarter of 2011 was primarily due to an increase in income tax expense related to an additional valuation allowance provided against the Company’s U.S. and certain states’ deferred tax assets.

Dr. Daniel Dosoretz, President and Chief Executive Officer, said, “Although we are seeing slight improvements in volume levels in our same practice centers, similar to other healthcare providers, we believe in many markets patients are continuing to postpone visits to their primary care physicians and other providers that can lead to the early diagnosis and treatment of cancer.

“We are very excited about the short and long term prospects associated with our March 1st acquisition of 26 radiation oncology centers in Latin America, a rapidly growing market. Leveraging this strong platform, we believe there are substantial opportunities to develop de novo centers and acquire additional centers, employing the clustering strategy that has proven successful for us in the U.S.

“During the first quarter, we continued to strengthen our management team with the appointment of Kurt Janavitz to the position of Senior Vice President of Managed Care and Network Development.  Kurt has more than 20 years experience in health care finance, strategy, operations and marketing and has worked extensively on the payer and provider sides of the business.

“Finally, we are pleased with the continued progress in other important initiatives, such as improvements to our clinical information technology systems to advance patient care, and the work associated with our role as developer and managing partner in the first proton beam center to be located in New York,” concluded Dr. Dosoretz.

Conference CallManagement will host a conference call Thursday, May 12, 2011 at 11:00 a.m. EDT to discuss financial results, other developments and business conditions. The dial-in numbers are (877) 407-4018 for domestic callers and (201) 689-8471 for international callers.  In addition, a telephonic replay of the call will be available until May 26, 2011.  The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers.  Please use the conference ID number 371043 to access the replay.  

About Radiation Therapy Services, Inc.Radiation Therapy Services, Inc., the Company’s wholly-owned operating subsidiary, which operates radiation treatment centers primarily under the name 21st Century Oncology, is a provider of advanced radiation therapy services to cancer patients. In total, Radiation Therapy Services, Inc. operates 118 treatment centers, including 91 centers located in 16 U.S. states, 26 centers located in six countries in Latin America and one center located in India.  Radiation Therapy Services, Inc. is headquartered in Fort Myers, Florida.


Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements are based on management’s current expectations or beliefs about the Company’s future plans, expectations and objectives, including, but not limited to, the Company’s expected financial results and estimates for 2011.  These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these forward-looking statements including, but not limited to the Company’s actual financial results and those risk factors that may be described from time to time in the Company’s filings with the Securities and Exchange Commission.  Readers of this release are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date stated, or if no date is stated, as of the date of this press release. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changed events or circumstances after the date of this release, unless required by law. Contact:
Amy Glynn / Nick Laudico
The Ruth Group
646-536-7023 / 7030
nlaudico@theruthgroup.comRADIATION THERAPY SERVICES HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) March 31, December 31, 20112010 (unaudited) ASSETS Current assets: Cash and cash equivalents

3,977Accounts receivable, net

94,23163,571Prepaid expenses


1,4091,426Deferred income taxes


8,1893,534 Total current assets

136,56891,753 Equity investments in joint ventures

3,74620,136 Property and equipment, net

239,018229,665 Real estate subject to finance obligation

9,5678,100 Goodwill

838,438770,898 Intangible assets, net

107,21085,236 Other assets

32,74430,542 Total assets

,236,330 LIABILITIES AND EQUITY Current liabilities: Accounts payable

21,888Accrued expenses

53,01035,765Income taxes payable

8,7555,994Current portion of long-term debt

8,8758,780Current portion of finance obligation

5453Other current liabilities

6,626197 Total current liabilities

105,12772,677 Long-term debt, less current portion

654,480590,051 Finance obligation, less current portion

10,0768,515 Other long-term liabilities

18,00815,981 Deferred income taxes

41,82733,527 Total liabilities

829,518720,751 Noncontrolling interests - redeemable

7,3227,371 Commitments and Contingencies Equity: Common stock, $0.01 par value, 1,025 shares authorized, 1,025 and ,000 shares issued and outstanding at March 31, 2011 and  December 31, 2010

--Additional paid-in capital

647,954630,989Retained deficit

(134,890)(130,374)Notes receivable from shareholder

(175)(175)Accumulated other comprehensive loss, net of tax

(1,884)(3,391)Total Radiation Therapy Services Holdings, Inc. shareholder's equity

511,005497,049Noncontrolling interests - nonredeemable

19,44611,159 Total equity

530,451508,208 Total liabilities and equity

,236,330RADIATION THERAPY SERVICES HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands) (unaudited) Three Months Ended March 31, 20112010 Revenues: Net patient service revenue

33,113 Other revenue

1,4541,420 Total revenues

156,537134,533 Expenses: Salaries and benefits

80,89969,664 Medical supplies

12,49110,813 Facility rent expense

7,8235,316 Other operating expenses

7,4586,244 General and administrative expenses

17,83614,268 Depreciation and amortization

12,45512,088 Provision for doubtful accounts

3,8012,739 Interest expense, net

14,49315,020 Gain on fair value adjustment of previously held  equity investment

(234)- Foreign currency transaction loss

10- Loss on forward currency derivative contracts

116- Total expenses

157,148136,152 Loss before income taxes

(611)(1,619) Income tax expense (benefit)

2,466(620) Net loss

(3,077)(999) Net income attributable to noncontrolling  interests- redeemable and non-redeemable

(1,439)(807) Net loss attributable to Radiation Therapy  Services Holdings, Inc. shareholder

(4,516)(1,806) Other comprehensive income: Unrealized gain on derivative interest rate swap  agreement and foreign currency translation, net of tax

1,169276 Comprehensive loss

(1,530)RADIATION THERAPY SERVICES HOLDINGS, INC. Supplemental Financial Information (Unaudited) Reconciliation of Pro-forma Adjusted EBITDA to Net Loss Attributable   to Radiation Therapy Services Holdings, Inc. Shareholder Three Months Ended March 31, 20112010 (in thousands): Total revenues

34,533 Pro-forma full period effect of acquisitions (a)

8,345- Total pro-forma revenues

34,533 Net loss attributable to Radiation Therapy  Services Holdings, Inc. shareholder

(1,806) Income tax expense (benefit)

2,466(620) Interest expense, net

14,49315,020 Depreciation and amortization

12,45512,088 Loss on forward currency derivative contracts

116- Gain on fair value adjustment of previously held  equity investment

(234)- Management fees (b)

277267 Non-cash expenses (c)

1,3421,086 Sale-lease back adjustments (d)

(196)(1,898) Acquisition-related costs (e)

1,64881 Other expenses (f)

321649 Litigation settlement (g)

-866 Pro-forma full period effect of acquisition EBITDA (a)

3,000- Pro-forma Adjusted EBITDA (1) $
25,733 Pro-forma Adjusted EBITDA as a percentage of  total pro-forma revenues

18.9%19.1%(1) Pro-forma Adjusted EBITDA is defined as income (loss) before interest expense (net of interest income), income taxes, depreciation and amortization, foreign currency hedge loss, gain on fair value adjustment of previously held equity investment management fees from our sponsor, non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to repairs and maintenance, sale-lease back adjustments, acquisition-related costs, other expenses including loss on sale of assets, severance payments related to termination of employee staff reductions and tail premiums on termed physicians, litigation settlements with physicians, change in accounting estimate physician compensation and pro-forma full period effect of acquisition EBITDA. (a) Pro-forma amounts related to adjustments to total revenues and Pro-forma Adjusted EBITDA to reflect the full period effect of our acquisition completed during 2011, including the purchase of the Medical Developers' physician practices in March 2011.  The adjustments reflect the impact to our total revenues and Pro-forma Adjusted EBITDA as if the acquisition had occurred at the beginning of the year. (b) Management fees are fees paid to our sponsor, Vestar Capital Partners. (c) Non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to warranty arrangements amortized to repairs and maintenance. (d) Sale-lease back adjustments relates to the adjustment of benefit derived from the classification of operating leases as finance obligations reflecting a reclassification of interest expense and depreciation and amortization expense as rent expense. (e) Acquisition related costs associated with the adoption of ASC 805, Business Combinations, requiring prior capitalized costs be expensed, including professional fees and due diligence costs relating to the acquisition of physician practices. (f) Other expenses include loss on sale of assets, severance payments related to termination of employee staff reductions and tail premiums paid on terminated physicians. (g) Litigation settlement relates to costs associated with the termination of physicians during 2010 as a result of the cost savings plans implemented in the fourth quarter of 2009. We believe the Pro-forma Adjusted EBITDA provides useful information about our financial performance to investors, lenders, financial analysts and rating agencies since these groups have historically used EBITDA-related measures in the healthcare industry, along with other measures, to estimate the value of a company, to make informed investment decisions, to evaluate a company's leverage capacity and its ability to meet its debt service requirements.  Pro-forma Adjusted EBITDA eliminates the uneven effect of non-cash depreciation of tangibles assets and amortization of intangible assets, much of which results from acquisitions accounted for under the purchase method of accounting.  Pro-forma Adjusted EBITDA is also used by us to measure individual performance for incentive compensation purposes and as an analytical indicator for purposes of allocating resources to our operating business and assessing their performance, both internally and relative to our peers, as well as to evaluate the performance of our operating management teams, and for purposes in the calculation of debt covenants and related disclosures. Pro-forma Adjusted EBITDA is not intended as a substitute for net income (loss) attributable to Radiation Therapy Services Holdings, Inc. shareholder, operating cash flows or other cash flow data determined in accordance with accounting principles generally accepted in the United States. Due to varying methods of calculation, Pro-forma Adjusted EBITDA as presented may not be comparable to similarly titled measures of other companies. RADIATION THERAPY SERVICES HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)Three months endedMarch 31,20112010Cash flows from operating activitiesNet loss$
(999)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation


1,6262,915Deferred rent expense

289557Deferred income taxes

1,9682,160Stock-based compensation

680250Provision for doubtful accounts

3,8012,739(Gain) loss on the sale of property and equipment

(8)415Loss on forward currency derivative contracts

116-Loss on foreign currency transactions

49-Gain on fair value adjustment of previously held equity investment

(234)-Amortization of debt discount

192302Amortization of loan costs

1,014707Equity interest in net loss (earnings) of joint ventures

250(165)Changes in operating assets and liabilities:Accounts receivable and other receivables

(15,597)(7,576)Income taxes payable

(337)(2,831)Inventories and other current assets

(677)62Prepaid expenses

7652,322Accounts payable

2,84482Accrued expenses

13,887(975)Net cash provided by operating activities

18,3809,138Cash flows from investing activitiesPurchase of property and equipment

(11,413)(6,782)Acquisition of medical practices

(42,104)(283)Proceeds from the sale of property and equipment

5263Repayments from employees

135216Contribution of capital to joint venture entities

-(2,633)Distribution received from joint venture entities

300-Proceeds from the sale of equity interest in a joint venture

312-Payment of foreign currency derivative contracts

(552)-Change in other assets and other liabilities

(60)(1,873)Net cash used in investing activities

(53,377)(11,092)Cash flows from financing activitiesProceeds from issuance of debt (net of original issue discount of $625)

49,401-Principal repayments of debt

(2,456)(3,609)Repayments of finance obligation

(13)(263)Proceeds from equity contribution

3-Payments of notes receivable from shareholder

-50Proceeds from issuance of noncontrolling interest

-608Cash distributions to noncontrolling interest holders - redeemable

-and non-redeemable

(923)(813)Deconsolidation of noncontrolling interest

-(14)Payments of debt issue costs

(1,534)-Net cash provided by (used in) financing activities

44,478(4,041)Effect of exchange rate changes on cash and cash equivalents

(3)-Net increase (decrease) in cash and cash equivalents

9,478(5,995)Cash and cash equivalents, beginning of period

13,97732,958Cash and cash equivalents, end of period

26,963Supplemental disclosure of non-cash transactionsRecorded noncash contribution of capital by noncontrolling interest holder

2Recorded noncash deconsolidation of noncontrolling interest

(64)Recorded finance obligation related to real estate projects

2,742Recorded derecognition of finance obligation related to real estate projects

(67,658)Recorded noncash distribution receivable and equity contribution payablefrom equity investee

75Recorded noncash use of vendor credit

,565Recorded issuance of Parent equity units related to the acquisition of medical practices

-Recorded issuance of senior subordinated notes related to the acquisition of medical practices$
-Recorded earn-out accrual related to the acquisition of medical practices

-RADIATION THERAPY SERVICES HOLDINGS, INC.KEY OPERATING STATISTICS(unaudited) Three Months Ended March 31, % 20112010ChangeNumber of treatment days (domestic U.S.)

6463Total RVU's - freestanding centers (domestic U.S.)

3,209,3412,753,62016.5%RVU's per day - freestanding centers (domestic U.S.)

50,14643,70814.7%Percentage change in RVU's per day - freestanding centers - same practice basis (domestic U.S.)

9.3%-0.8%Number of regions at period end

98Number of local markets at period end (domestic U.S.)

2828Treatment centers - freestanding

1129123.1%Treatment centers - hospital / other groups

67-14.3%1189820.4%Days sales outstanding at quarter end (domestic U.S.)

4041Percentage change in freestanding revenues- same practice basis (domestic U.S.)

3.3%-5.0%Net patient service revenue - professional services only (in thousands) (domestic U.S.)


SOURCE Radiation Therapy Services Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing
2. Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
3. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
4. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
5. Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices
6. Nottingham University Hospital is First U.K. User of Elektas Electronic Medical Record Workspace for Image Guided Radiation Therapy
7. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
8. The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation
9. Radiation Therapy Services Holdings, Inc. Acquires Medical Developers, LLC
10. PreXion Launches New Faster, Lower Radiation PreXion3D Elite Cone Beam Imaging System
11. Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer
Post Your Comments:
(Date:10/13/2015)... 2015  Data Science Automation (DSA), a system integration and ... branch office in the United Kingdom ... Europe . The decision to open the new ... support of customers in the medical device industry throughout the ... Manager. "We have had tremendous success over the last several ...
(Date:10/13/2015)...  Nanomedical Diagnostics, a biotech company developing and ... announces the completion of a Series A financing ... --> --> ... and diagnostic platforms that empower individuals to make ... enable the company to commercially release AGILE Research, ...
(Date:10/13/2015)... COLLEGE PARK, Md. , Oct. 13, 2015 ... hubs is the biggest key to growing Baltimore ... to a report released today by the Maryland Technology ... already has many of the pieces in place to support ... Martha Connolly , director of Mtech Baltimore. "This study is ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., the ... the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take place the week ... are independent user conferences designed and led by users to provide attendees with ...
(Date:10/13/2015)... Hollywood, CA (PRWEB) , ... October 13, 2015 , ... ... published by Medical New Today on September 18, 2015. The research, which was conducted ... by Dr. Wael Sabbah and colleagues, show connections between stress during pregnancy and future ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. ... bone, and blood. But how much protein does the average man need in order ... according to the October 2015 issue of Harvard Men's Health Watch . Most ...
(Date:10/13/2015)... ... October 13, 2015 , ... Georgia Partnership ... in communities throughout Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) ... telehealth summits for Fall 2015. , Each of the three conferences share ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN report ... when a teammate accidentally elbowed him in the left eye during the first day ... just one of a series of setbacks, including a knee injury that has interfered ...
Breaking Medicine News(10 mins):